NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, highlighted the potential of its broad-spectrum antiviral candidate NV-387 in response to the ongoing Bundibugyo Ebola outbreak in the Democratic Republic of Congo and Uganda. The company stated that the oral drug candidate could offer a differentiated approach if proven effective against the virus strain. NanoViricides emphasized NV-387’s proposed mechanism targeting viral cell attachment pathways common across filoviruses, positioning the candidate as a potential pandemic preparedness tool for Ebola and related viral threats.
The announcement comes as health authorities monitor the outbreak, underscoring the need for novel antiviral treatments. NV-387 is being developed for multiple viral indications, including respiratory syncytial virus (RSV), COVID-19, influenza, and mpox. The company is currently focused on advancing NV-387 into Phase II human clinical trials. According to the press release, the drug candidate’s ability to target conserved viral entry mechanisms may provide a strategic advantage against emerging viral strains.
NanoViricides’ platform technology is based on the TheraCour nanomedicine technology, which the company licenses from AllExcel. The company holds a worldwide exclusive perpetual license for several drugs targeting human viral diseases, including HIV/AIDS, hepatitis B and C, rabies, herpes, influenza, dengue, Ebola, and coronaviruses. The company’s lead drug candidate NV-387 is a broad-spectrum antiviral that does not encapsulate remdesivir, while NV-CoV-2-R encapsulates remdesivir within its polymeric micelles. The company believes that since remdesivir is already FDA-approved, NV-CoV-2-R could be an approvable drug if safety is comparable.
NanoViricides noted that the path to drug development is extremely lengthy and requires substantial capital, and there can be no assurance that any of its candidates will show sufficient effectiveness and safety for human clinical development. The company’s full press release is available at https://ibn.fm/mm3Z5. For more information about NanoViricides, visit https://www.nanoviricides.com.
InvestorWire, a specialized communications platform, syndicated this press release. InvestorWire is part of the Dynamic Brand Portfolio @IBN, which provides access to a network of wire solutions, editorial syndication, and social media distribution. For more details, see https://www.InvestorWire.com and the full terms of use and disclaimers at https://www.InvestorWire.com/Disclaimer.
